Weil, Cooley Steer Sanofi's $2.5B Cancer Therapy Buy
Sanofi said Monday it will bolster its cancer therapies pipeline by acquiring clinical-stage biotechnology company Synthorx in a roughly $2.5 billion deal steered by Weil Gotshal & Manges LLP and Cooley...To view the full article, register now.
Already a subscriber? Click here to view full article